BRUSSELS and AIX-LA-CHAPELLE, Germany, January 24, 2022 /PRNewswire/ — The European Pain Federation EFIC® and the pharmaceutical company Grünenthal announced the five winners of the EFIC-Grünenthal (EGG) scholarship. Worth a total of €200,000, this biennial grant rewards innovative projects for human pain research and supports promising scientists and doctors at the start of their careers.
Pain is a major health problem
One in five people in Europe live with chronic pain and this number is likely to increase as the aging population grows. Pain has a negative impact on quality of life and creates a significant economic and social burden. The direct and indirect health costs of chronic pain in European Union countries are estimated at 2-3% of gross domestic product (GDP).,
The EGG aims to raise awareness of unmet pain management needs. It supports young scientists by helping them explore new ideas for pain research projects. The grant can be up to €40,000 per project. The winners are selected by the independent EFIC® Research Committee, a multidisciplinary team of experts in the field of pain. The selection criteria include the originality of the project and the potential clinical impact. In addition to financial support, recipients also have the opportunity to network with pain research experts and communicate their research findings to the scientific community at the biannual Pain in Europe Congress.
“For more than 15 years, the EGG Fellowship has enabled young scientists and clinicians to become independent researchers in the field of pain. The quality, diversity and originality of the many proposals received for EGG 2022 hold promise for the future of pain research. each proposal was scientifically stimulating,” says Professor André Mouraux, President of EFIC® Scientific Research Committee and one of the 2008 EGG Laureates.
The 2022 EGG winners
EGG received 79 applications. In a two-stage evaluation, seven selected evaluators and four EFIC members® The Grants and Awards Research Committee Working Group selected five research projects for funding:
Project title: Stress intolerance in patients with diffuse chronic pain: are epigenetic mechanisms the answer to the mystery?
- Roberta Gualdani, Belgium
Project title: Potential transient receptor channels as new targets for precision pain medicine
- Alberto Gonzalez Villar, Portugal
Project title: Evaluation of the analgesic effects of interpersonal/affective touch during the induction of secondary hyperalgesia and temporal summation of second pain
- Cindy Germaine Boer, Netherlands
Project title: Osteoarthritis, a visceral sensation? the intestinal microbiome as a new therapeutic target for osteoarthritis pain
- Shafaq Sikandar, UK
Project title: Identification of a composite biomarker signature for chronic pain in early rheumatoid arthritis
The winners will be officially recognized at the opening ceremony of the 12th Congress of the European Pain Federation EFIC® in Dublin, Irelandfrom 27 to April 30, 2022.
The day after the ceremony, representatives from previous EGG winning projects will share insights into their research activities at the symposium “EGG: New Findings in Clinical Pain Research”.
For more information, visit www.egg.info
About the European Pain Federation EFIC®
Based at Brussels, the European Pain Federation EFIC® is a multidisciplinary professional organization in the field of pain research and pain management, made up of the 38 chapters of the International Association for the Study of Pain (IASP® ), the official national pain societies approved by the IASP® in each country. Established in 1993, the constituent chapters of the European Pain Federation EFIC® represent pain societies from 38 European countries and over 20,000 physicians, basic researchers, nurses, physiotherapists, psychologists and other healthcare professionals across the world. Europewho are involved in pain management and pain research
For more information: www.europeanpainfederation.eu
Grünenthal is a world leader in the management of pain and related diseases. As a fully integrated, science-based pharmaceutical company, we have a long history of delivering innovative treatments and breakthrough technologies to patients around the world. Our goal is to change lives for the better – and innovation is our passion. We focus all of our activities and efforts on realizing our vision of a pain-free world.
Grünenthal is headquartered in Aachen, Germanyand has subsidiaries in 29 countries across Europe, Latin America and the United States. Our products are available in hundreds of countries. In 2020, Grünenthal employed around 4,500 people and achieved a turnover of 1.3 billion euros.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
European Pain Federation EFIC®
Grensstraat 7, mailbox 3
Fax: +32 2 251 48 10
E-mail: [email protected]
Global Business Communications Manager
E-mail: [email protected]
Telephone: +447917 196855
 Goldberg DS, McGee SJ. BMC Public Health 2011, 11:770.
 Varassi G, et al. Current opinion of Res. med. 2010;26:1231–45.
 Rice ASC, et al. Pain. 2016;157(4):791–6.
 Wiffen P. Pain: There are many. Eur J Hosp Pharm. 2013;20:1.
 Bevan S et al. Reducing temporary absence from work through early intervention: the case of MSDs in the EU. The Labor Foundation. 2013.
 Breivik H, et al. The individual and societal burden of chronic pain in Europe: the case for strategic prioritization and action to improve knowledge and availability of appropriate care. BMC Public Health. December 24, 2013, flight. 13, 1229.
SOURCE Grünenthal Group